Abstract 2137
Background
The management of papillary thyroid carcinoma (PTC) should be decided by Risk-adapted approach. However, intermediated risk PTC needs to be stratified more precisely. Otherwise, the utility of 18F-FDG PET images in patients with PTC is restrictive. The aim of this study was to investigate the prognostic value of Metabolic Tumor Volume (MTV) measured on 18F-FDG PET images in patients with papillary thyroid carcinoma treated with surgery.
Methods
We retrospectively analyzed 102 patients with PTC who underwent 18F-FDG PET/CT between Feburary 2009 and June 2017 at Osaka University Medical School Hospital for initial staging before surgery. We evaluated the association of MTV of primary tumor (T-MTV) with relapse-free survival (RFS) using Cox regression analysis. Receiver operating characteristic (ROC) curves were used to estimate the optimal cut-off values for T-MTV. We also conducted recursive partitioning analyses to offer a novel risk stratification system.
Results
The 3-year RFS for all patients were 81.2% with median follow-up of 42 months (range 11-111). In Cox model, T-MTV (Hazard Ratio, 1.23; 95% CI, 1.08 to 1.38; P = 0.002) was significantly associated with RFS. ROC analyses showed that the optimal cutoff value of T-MTV was 10.3ml. We classified the patients as having a low, intermediate, or high risk of relapse or death on the basis of T-MTV and lymph node metastasis.
Conclusions
MTV of primary tumor was a significant prognostic factor for RFS in patients with PTC treated with surgery. Incorporation of T-MTV into staging may lead to a better risk stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract
3191 - The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma - A nationwide multicenter study in Japan-
Presenter: Azusa Sakamoto
Session: Poster Display session 2
Resources:
Abstract
1529 - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase 3 studies (REACH, REACH-2)
Presenter: Andrew Zhu
Session: Poster Display session 2
Resources:
Abstract
2767 - Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
Presenter: Nicholas Freemantle
Session: Poster Display session 2
Resources:
Abstract
2150 - Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Poster Display session 2
Resources:
Abstract
3437 - Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis
Presenter: Marc Pracht
Session: Poster Display session 2
Resources:
Abstract
1758 - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase 3 trials (REACH and REACH-2)
Presenter: Masatoshi Kudo
Session: Poster Display session 2
Resources:
Abstract
1192 - Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure–response analysis
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1600 - Outcomes of Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab: The Mount Sinai Hospital Experience.
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2364 - Pembrolizumab vs Chemotherapy in Patients With Advanced/Metastatic Adenocarcinoma (AC) or Squamous Cell Carcinoma (SCC) of the Esophagus as Second-Line Therapy: Analysis of the Chinese Subgroup in KEYNOTE-181
Presenter: Jia Chen
Session: Poster Display session 2
Resources:
Abstract